시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 맞춤형 유전자 치료 시장 보고서(2025년)
Personalized Gene Therapy Treatment Global Market Report 2025
상품코드 : 1855947
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,693,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,675,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,656,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

맞춤형 유전자 치료 시장 규모는 최근 급격히 확대되고 있습니다. 2024년 69억 3,000만 달러로 평가되었고, 2025년에는 83억 8,000만 달러에 달하고, CAGR 20.8%로 성장할 전망입니다. 실적 기간 동안의 성장은 유전성 질환의 유병률 증가, 유전자 편집 기술의 진보, 맞춤형 의료에 대한 의식 증가, 정부의 지원 이니셔티브와 자금 제공, 생명공학 연구와 인프라의 확대가 원동력이 되고 있습니다.

맞춤형 유전자 치료 시장 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년에는 CAGR 20.5%로 176억 5,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 유전자 요법의 임상시험 확대, 치료 설계의 인공지능과 예측 분석의 통합, 제약 기업과 생명 공학 기업 간의 협력 관계 증가,보다 안전하고 효율적인 전달 벡터 개발, 표적 및 정밀 치료에 대한 수요 증가로 촉진됩니다. 예측기간의 주요 동향으로는 치료 디자인에 있어서의 인공지능과 머신러닝의 통합, 유전체 시퀀싱 능력의 확대, 바이오테크놀러지 기업과 제약 기업간의 협력 관계의 확대, 유전자 치료 제조 공정의 자동화, 유전자 데이터 보안을 위한 블록체인 기술의 채택 등을 들 수 있습니다.

유전성 질환의 유병률 증가는 맞춤형 유전자 치료 시장의 성장을 가속할 것으로 예측됩니다. 유전성 질환은 정상적인 신체 기능을 저해하는 DNA 이상으로부터 발생하며, 그 유병률은 부모의 나이가 상승하고 노인 생식 세포가 자손에게 돌연변이를 전달할 위험이 높아지는 등의 요인에 의해 상승하고 있습니다. 맞춤형 유전자 치료는 질병을 일으키는 결함 유전자를 직접 수정하고 개인의 유전자 프로파일을 기반으로 치료를 사용자 정의함으로써 해결책을 제공합니다. 이 접근법은 치료 효과를 높이고 부작용을 줄입니다. 예를 들어, 2023년 9월, 낭포성 섬유증 트러스트는 영국의 낭포성 섬유증(CF) 환자 수가 2021년 1만 908명에서 2022년 1만 1,148명으로 증가했다고 보고했습니다. 그 결과, 유전성 질환의 유병률 증가가 맞춤형 유전자 치료 시장의 확대에 기여하고 있습니다.

맞춤형 유전자 치료 시장의 주요 기업은 기술력을 강화하고 혁신적인 치료법 제공을 가속화하기 위해 전략적 파트너십에 주력하고 있습니다. 이러한 파트너십을 통해 기업은 자원과 전문 지식을 결합하여 신개발 위험과 수익을 모두 공유할 수 있습니다. 예를 들어, 2025년 5월, DNA, RNA, 단백질 생산을 전문으로 하는 미국의 알데브론은 유전체학 솔루션공급자인 미국의 Integrated DNA Technologies와 제휴하여 우레아 사이클 장애(UCD)라고 불리는 희귀하고 생명을 위협하는 유전성 질환에 대한 세계 최초의 mRNA 기반의 개별화 CRISPR 요법을 개발했습니다. 이 "N of 1" 요법은 맞춤 가이드 RNA, mRNA 코딩 기반 편집기, 오프 타겟 안전 서비스, 임상적으로 검증된 지질 나노 입자 전달 시스템을 통합하여 단 6개월 만에 개발했습니다. 이 치료의 성공은 개인화된 생체내 염기 편집 치료에서 중요한 이정표가 될 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Personalized gene therapy treatment refers to specialized medical care that delivers targeted therapies tailored to an individual's unique genetic profile. It involves modifying, repairing, or replacing faulty genes to directly address the root causes of genetic disorders. Personalized gene therapy treatment improves precision of care, reduces the risk of adverse effects, and enhances overall therapeutic outcomes.

The primary types of personalized gene therapy treatments include targeted treatments and pharmacogenomics. Targeted treatments are therapies specifically designed to modify or regulate particular genes linked to a disease in order to maximize therapeutic benefit while minimizing side effects. The vector types include viral and nonviral approaches and are administered through various distribution channels such as hospitals, clinics, home administration, and others. These treatments are applied across diverse medical areas, including oncology, neurology, hematology, infectious diseases, ophthalmology, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The personalized gene therapy treatments market research report is one of a series of new reports from The Business Research Company that provides personalized gene therapy treatments market statistics, including personalized gene therapy treatments industry global market size, regional shares, competitors with a personalized gene therapy treatments market share, detailed personalized gene therapy treatments market segments, market trends and opportunities, and any further data you may need to thrive in the personalized gene therapy treatments industry. The personalized gene therapy treatments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The personalized gene therapy treatment market size has grown exponentially in recent years. It will grow from $6.93 billion in 2024 to $8.38 billion in 2025 at a compound annual growth rate (CAGR) of 20.8%. The growth during the historic period is driven by the increasing prevalence of genetic disorders, progress in gene editing technologies, rising awareness of personalized medicine, supportive government initiatives and funding, and expansion of biotechnology research and infrastructure.

The personalized gene therapy treatment market size is expected to see exponential growth in the next few years. It will grow to $17.65 billion in 2029 at a compound annual growth rate (CAGR) of 20.5%. The growth during the forecast period is fueled by the expansion of clinical trials for gene therapies, the integration of artificial intelligence and predictive analytics in treatment design, increasing collaborations between pharmaceutical and biotechnology companies, the development of safer and more efficient delivery vectors, and the rising demand for targeted and precision therapies. The primary trends in the forecast period include integration of artificial intelligence and machine learning in therapy design, expansion of genomic sequencing capabilities, growth in collaborations between biotechnology and pharmaceutical companies, automation in gene therapy manufacturing processes, and adoption of blockchain technology for genetic data security.

The increasing prevalence of genetic disorders is expected to drive the growth of the personalized gene therapy treatment market. Genetic disorders arise from DNA abnormalities that disrupt normal bodily functions, and their prevalence is rising due to factors such as increasing parental age, where older reproductive cells carry a higher risk of passing mutations to offspring. Personalized gene therapy offers a solution by directly correcting the faulty genes responsible for the condition and customizing treatment based on an individual's genetic profile. This approach enhances the efficacy of treatment and reduces side effects. For example, in September 2023, the Cystic Fibrosis Trust reported that the number of cystic fibrosis (CF) patients in the UK increased to 11,148 in 2022, up from 10,908 in 2021. As a result, the growing prevalence of genetic disorders is contributing to the expansion of the personalized gene therapy treatment market.

Key players in the personalized gene therapy treatment market are focusing on strategic partnerships to enhance their technological capabilities and accelerate the delivery of innovative therapies. These partnerships allow companies to combine resources and expertise, sharing both the risks and rewards of new developments. For example, in May 2025, Aldevron, a US-based company specializing in the production of DNA, RNA, and proteins, partnered with Integrated DNA Technologies, a US-based provider of genomics solutions, to create the world's first mRNA-based personalized CRISPR therapy for a rare and life-threatening genetic condition called urea cycle disorder (UCD). This "N of 1" therapy was developed in just six months, incorporating a custom guide RNA, mRNA-encoded base editor, off-target safety services, and a clinically validated lipid nanoparticle delivery system. The success of this therapy represents a significant milestone in personalized in vivo base-editing treatments.

In July 2025, Eli Lilly and Company, a US-based pharmaceutical company, acquired Verve Therapeutics Inc. for $1.3 billion. This acquisition allows Eli Lilly to expand its gene-editing portfolio into cardiovascular diseases and strengthens its position in the personalized gene therapy market. Verve Therapeutics, a clinical-stage company, is focused on developing one-time base-editing gene therapies specifically for cardiovascular conditions.

Major players in the personalized gene therapy treatment market are Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Kyowa Kirin Co. Ltd., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Rocket Pharmaceuticals Inc., REGENXBIO Inc., Intellia Therapeutics Inc., Beam Therapeutics Inc., Adaptimmune Therapeutics plc, Krystal Biotech Inc., Miltenyi Biomedicine GmbH, Bluebird Bio Inc., uniQure N.V., Mesoblast Limited, Astellas Gene Therapies Inc., Adverum Biotechnologies Inc., Autolus Therapeutics plc.

North America was the largest region in the personalized gene therapy treatment market in 2024. The regions covered in personalized gene therapy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the personalized gene therapy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The personalized gene therapy treatment market consists of revenues earned by entities by providing services such as genetic testing and diagnostics, personalized therapy design, gene editing treatments, viral and non-viral vector delivery, patient-specific cell therapies, and post-treatment monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized gene therapy treatment market also includes sales of viral vectors, gene editing platforms, cell culture systems, bioprocessing tools, and monitoring software. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Personalized Gene Therapy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on personalized gene therapy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for personalized gene therapy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The personalized gene therapy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Personalized Gene Therapy Treatment Market Characteristics

3. Personalized Gene Therapy Treatment Market Trends And Strategies

4. Personalized Gene Therapy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Personalized Gene Therapy Treatment Growth Analysis And Strategic Analysis Framework

6. Personalized Gene Therapy Treatment Market Segmentation

7. Personalized Gene Therapy Treatment Market Regional And Country Analysis

8. Asia-Pacific Personalized Gene Therapy Treatment Market

9. China Personalized Gene Therapy Treatment Market

10. India Personalized Gene Therapy Treatment Market

11. Japan Personalized Gene Therapy Treatment Market

12. Australia Personalized Gene Therapy Treatment Market

13. Indonesia Personalized Gene Therapy Treatment Market

14. South Korea Personalized Gene Therapy Treatment Market

15. Western Europe Personalized Gene Therapy Treatment Market

16. UK Personalized Gene Therapy Treatment Market

17. Germany Personalized Gene Therapy Treatment Market

18. France Personalized Gene Therapy Treatment Market

19. Italy Personalized Gene Therapy Treatment Market

20. Spain Personalized Gene Therapy Treatment Market

21. Eastern Europe Personalized Gene Therapy Treatment Market

22. Russia Personalized Gene Therapy Treatment Market

23. North America Personalized Gene Therapy Treatment Market

24. USA Personalized Gene Therapy Treatment Market

25. Canada Personalized Gene Therapy Treatment Market

26. South America Personalized Gene Therapy Treatment Market

27. Brazil Personalized Gene Therapy Treatment Market

28. Middle East Personalized Gene Therapy Treatment Market

29. Africa Personalized Gene Therapy Treatment Market

30. Personalized Gene Therapy Treatment Market Competitive Landscape And Company Profiles

31. Personalized Gene Therapy Treatment Market Other Major And Innovative Companies

32. Global Personalized Gene Therapy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Personalized Gene Therapy Treatment Market

34. Recent Developments In The Personalized Gene Therapy Treatment Market

35. Personalized Gene Therapy Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기